Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.62−0.01 (-0.61%)
Close on Nov 18, 2026Market cap $2.64MP/E –Yield –
Ernexa Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Ernexa Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$7.05M. For fiscal 2025 it was -$7.05M. The highest annual figure on record is $2.62M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.05M | – |
| FY2024 | Dec 31, 2024 | -$16.21M | – |
| FY2023 | Dec 31, 2023 | -$20.43M | – |
| FY2022 | Dec 31, 2022 | -$21.27M | – |
| FY2021 | Dec 31, 2021 | -$23.64M | – |
| FY2020 | Dec 31, 2020 | -$8.14M | -411.2% |
| FY2019 | Dec 31, 2019 | $2.62M | +264.9% |
| FY2018 | Dec 31, 2018 | $717.00K | – |
| FY2017 | Dec 31, 2017 | -$179.00K | – |
| FY2016 | Dec 31, 2016 | -$404.00K | – |
| FY2015 | Dec 31, 2015 | -$5.17M | – |
| FY2014 | Dec 31, 2014 | -$7.22M | -1242.4% |
| FY2013 | Dec 31, 2013 | $632.00K | -32.0% |
| FY2012 | Dec 31, 2012 | $930.00K | – |
| FY2011 | Dec 31, 2011 | -$1.02M | -167.6% |
| FY2010 | Dec 31, 2010 | $1.51M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.16M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.55M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.30M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.51M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.85M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.68M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.83M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.87M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.46M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.16M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.18M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.98M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.43M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.80M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.43M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.65M | -270.9% |
| Q3 FY2020 | Sep 30, 2020 | -$2.41M | -717.1% |
| Q2 FY2020 | Jun 30, 2020 | -$2.21M | -523.3% |
| Q1 FY2020 | Mar 31, 2020 | -$1.88M | -354.1% |
| Q4 FY2019 | Dec 31, 2019 | $966.00K | +101.3% |
| Q3 FY2019 | Sep 30, 2019 | $390.00K | +40.3% |
| Q2 FY2019 | Jun 30, 2019 | $521.00K | +110.1% |
| Q1 FY2019 | Mar 31, 2019 | $739.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $480.00K | – |
| Q3 FY2018 | Sep 30, 2018 | $278.00K | – |
| Q2 FY2018 | Jun 30, 2018 | $248.00K | -91.8% |
| Q1 FY2018 | Mar 31, 2018 | -$289.00K | – |
| Q4 FY2017 | Dec 31, 2017 | -$673.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.97M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.03M | – |
| Q1 FY2017 | Mar 31, 2017 | -$563.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$70.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$56.00K | – |
See a number that looks wrong?